What type of study is this?

October 23, 2025Open Access

Versatility of autologous growth factor concentrate therapy in early-stage androgenetic alopecia: A case report

Puntos clave

Hair density increased from 72 to 98 hairs/cm² after treatment with autologous growth factor concentrate, showing significant improvement.
Patient satisfaction was rated 9 out of 10, indicating strong approval of the treatment's effects.
Treatment involved standardized injections of growth factor concentrate over four sessions with no adverse effects reported.
These findings highlight that regenerative approaches could be a viable option for managing early-stage androgenetic alopecia.

Resumen

Androgenetic alopecia (AGA) is a common progressive condition in men, influenced by genetic predisposition and androgen sensitivity. Conventional therapies such as minoxidil and finasteride provide limited efficacy and require long-term use, often associated with side effects. Regenerative approaches like autologous growth factor concentrate (GFC) have emerged as promising alternatives. This report presents a 28-year-old male with Norwood–Hamilton Grade III vertex AGA, treated with standardized GFC injections administered monthly for four sessions. Post-treatment, the patient demonstrated reduced hair shedding, improved density (72 to 98 hairs/ cm 2 ), and an 18% increase in shaft thickness, with no adverse effects. Patient satisfaction was rated 9/10. These findings suggest that GFC is a safe, effective, and minimally invasive modality for early AGA management.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo